1. Melo GM, Sguilar DA, Petiti CM, Eichstaedt AG, Caiado RR, Souza RA. Concomitant thyroid MALT lymphoma and papillary thyroid carcinoma. Arq Bras Endocrinol Metabol. 2010; 54(4):425–8.
Article
2. Cheng V, Brainard J, Nasr C. Co-occurrence of papillary thyroid carcinoma and primary lymphoma of the thyroid in a patient with long-standing Hashimoto's thyroiditis. Thyroid. 2012; 22(6):647–50.
Article
3. Tarui T, Ishikawa N, Kadoya S, Watanabe G. Co-occurrence of papillary thyroid cancer and MALT lymphoma of the thyroid with severe airway obstruction: a case report and review of the literature. Int J Surg Case Rep. 2014; 5(9):594–7.
Article
4. Thieblemont C, Mayer A, Dumontet C, Barbier Y, Callet-Bauchu E, Felman P, et al. Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metab. 2002; 87(1):105–11.
Article
5. Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol. 1999; 111(1 Suppl 1):S8–12.
6. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84(5):1361–92.
7. Hyjek E, Isaacson PG. Primary B cell lymphoma of the thyroid and its relationship to Hashimoto's thyroiditis. Hum Pathol. 1988; 19(11):1315–26.
Article
8. Nam YJ, Kim BH, Lee SK, Jeon YK, Kim SS, Jung WJ, et al. Co-occurrence of papillary thyroid carcinoma and mucosaassociated lymphoid tissue lymphoma in a patient with longstanding hashimoto thyroiditis. Endocrinol Metab (Seoul). 2013; 28(4):341–5.
Article
9. Matsuzuka F, Miyauchi A, Katayama S, Narabayashi I, Ikeda H, Kuma K, et al. Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. Thyroid. 1993; 3(2):93–9.
Article
10. Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003; 21(22):4157–64.
Article
11. Kahara T, Iwaki N, Kaya H, Kurokawa T, Yoshida T, Ishikura K, et al. Transition of thyroid autoantibodies by rituximab treatment for thyroid MALT lymphoma. Endocr J. 2011; 58(1):7–12.
Article
12. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008; 9(2):105–16.
Article
13. Lee SC, Hong SW, Lee YS, Jeong JJ, Nam KH, Chung WY, et al. Primary thyroid mucosa-associated lymphoid tissue lymphoma; a clinicopathological study of seven cases. J Korean Surg Soc. 2011; 81(6):374–9.
Article